Atomo Diagnostics

Atomo Diagnostics is an Australian-headquartered, publicly traded (ASX:AT1) medical device company specializing in the development and commercialization of integrated, user-friendly rapid diagnostic test platforms for professional and self-test applications. Their flagship HIV Self Test is FDA, TGA, CE, and WHO-approved, known for its high sensitivity (99.6%), specificity (99.6%), and ease of use. The company's platform technology, which integrates sample collection and processing, is also leveraged by partners for custom rapid diagnostic development, demonstrating a platform business model with digital health integration capabilities.